Iron Deficiency Anemia Clinical Trial
Official title:
Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants
It is common in many populations that babies develop iron deficiency or iron deficiency anemia (that is, too few healthy red blood cells due to lack of iron). This is due to rapid growth in infancy combined with limited sources of iron in the infant diet. The amount of iron the baby receives across the placenta during pregnancy is another important factor. This study focuses on infants who are born with less than the usual amount of iron in their bodies. The purposes of the study are to assess effects of lower iron at birth on infant behavior and development and to determine if providing iron supplements to such infants beginning at 6 weeks fosters healthier development. Another part of the study will determine the effects of iron deficiency anemia at different times during infant development.
The project focuses on brain-behavior effects depending on the timing of iron deficiency
(ID) and iron repletion in human infants. Iron deficiency (ID) is the world's most common
single nutrient disorder, differentially affecting pregnant women and infants everywhere.
The study promises to be the first systematic investigation of brain and behavior effects of
prenatal dietary iron deficiency in human infants. The design will support comparisons of
brain/behavior effects depending on the timing and duration of ID. The study will assess
reversibility of effects, depending on timing of ID and its treatment, and examine maternal
vs. fetal iron regulatory mechanisms in placenta and white blood cells. State-of-the-art
neurophysiologic and behavioral measures will test specific hypotheses regarding effects of
ID on sensory, motor, cognitive, affective-social and regulatory functions related to
impaired myelination of sensory/motor systems and altered structure, neurotransmitter
function and neurometabolism in targeted brain regions (basal ganglia and hippocampus). The
study will be conducted in China, a rapidly developing country where ID often occurs among
pregnant women and infants in the absence of generalized undernutrition. Cord blood
hemoglobin (Hb) and ferritin concentrations will be measured in 1300 rural full-term
infants, with iron status determined again at 9 and 18 mo. Brain-behavior assessments in the
perinatal period will involve 359 infants ("newborn cohort"): 59 with low Hb ("low birth
iron" group) will receive iron; 200 with marginal Hb or low cord ferritin ("marginal birth
iron" group) will be randomly assigned at 6 wk, 50 to iron therapy and 150 to vitamins only;
and 100 with normal cord Hb and ferritin levels ("normal birth iron" group) will receive
vitamins only. The remaining 763 infants with cord blood testing will form the "blood screen
cohort." At 9 and 18 mo, the newborn cohort will be reassessed, along with IDA infants from
the blood screen cohort - about 58 at 9 mo ("early postnatal IDA") and 48 at 18 mo ("late
postnatal IDA"). Approximately 39 marginal-birth-iron vitamins only-treated infants in the
newborn cohort may also have IDA at 9 mo ("combined ID"). IDA infants will be treated with
vitamins with iron. Differential effects and/or reversibility depending on timing of ID or
treatment could inform health policy and practice worldwide. However, the effects of
prenatal iron deficiency have received very little study in human infants due in large part
to previous thinking, no longer accepted, that the infant was protected. Up to 75% of
pregnant women worldwide are anemic, with about half due to ID. An estimated 20-25% of 6- to
24-mo-old infants have IDA, and more have ID without anemia. Thus, the public health
implications of study findings could be profound.
The project is expected to continue with a 5-year follow-up (Aug 2013-July 2017).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06027801 -
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
|
N/A | |
Completed |
NCT02282553 -
Gastric Capsule Examination for Iron Deficiency Anaemia
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT04913649 -
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
|
Phase 4 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT01307007 -
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
|
Phase 2 | |
Completed |
NCT00982007 -
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
|
Phase 3 | |
Completed |
NCT00198848 -
Iron Supplementation Among Adolescent Girls in India
|
N/A | |
Completed |
NCT01166451 -
The Anemia Control Program: High or Low Iron Supplementation
|
N/A | |
Recruiting |
NCT03893045 -
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
|
Phase 3 | |
Recruiting |
NCT03817957 -
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
|
Phase 3 | |
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Completed |
NCT03618914 -
Anemia and Inflammation
|
||
Completed |
NCT03940430 -
Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Completed |
NCT03237065 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT05153278 -
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
|